Sensex, Nifty Extend Recent Losses On Tariff Worries

Indian equities traded lower, with the BSE Sensex and NSE Nifty both declining approximately 0.4%, primarily influenced by new U.S. tariff announcements on heavy trucks, drugs, and kitchen cabinets. The IT sector, including Infosys and TCS, saw 1-2% losses following Accenture's cautious FY26 guidance, while Sun Pharma dropped 2% due to proposed U.S. pharmaceutical import tariffs. Counteracting the broader market trend, Maruti Suzuki gained 1% on strong festive season bookings, Hindustan Aeronautics advanced 1.4% after securing a government deal for fighter jets, and RITES surged 5.4% on an $18 million international order.

Analysis

Indian equity markets are facing a dual-pronged pressure from external factors, causing the BSE Sensex and NSE Nifty to decline by 0.4%. Firstly, renewed U.S. trade protectionism, including new tariffs on various goods and a specific threat of up to 100% tariffs on pharmaceutical imports from October 2025, has directly impacted sentiment and specific stocks like Sun Pharma, which fell 2%. Secondly, the Indian IT sector is experiencing a broad sell-off, with major firms including Infosys and TCS declining 1-2%. This weakness is a contagion effect from Accenture's cautious FY26 guidance and significant restructuring announcement, signaling potential headwinds for the global IT services industry. In contrast to these macro-driven declines, several companies are showing idiosyncratic strength. Maruti Suzuki's 1% gain reflects robust domestic consumer demand driven by festive season sales. Furthermore, companies with strong order books from government and international contracts, such as Hindustan Aeronautics (+1.4%), Ceigall India (+1%), and RITES (+5.4%), are outperforming, indicating that sectors insulated from global trade disputes and reliant on domestic or specialized demand remain resilient.

Key Decisions for Investors

• Investors should exercise caution with Indian IT service providers like Infosys and Wipro, as Accenture's negative guidance suggests potential for slowing global demand and margin pressure across the sector.
• Re-evaluate exposure to export-oriented pharmaceutical companies like Sun Pharma, as the proposed 2025 U.S. tariffs, while distant, introduce significant long-term regulatory and pricing risk.
• Consider focusing on companies with strong domestic catalysts, particularly in the automotive, defense, and infrastructure sectors, which are demonstrating resilience to global macro headwinds through strong order flow and local demand.
• Given the divergence between sectors, a stock-picker's approach may be more effective than broad index exposure, prioritizing firms with secured contracts and strong domestic market positioning.